Oxaprotiline

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Oxaprotiline
Accession Number
DB09307
Type
Small Molecule
Groups
Experimental
Description

Oxaprotiline is a norepinephrine reuptake inhibitor of the tetracyclic antidepressant family that is related to maprotiline. Though investigated as an antidepressant, it was never marketed. Oxaprotiline is a racemic compound composed of two isomers, R(−)- or levo- oxaprotiline (levoprotiline; CGP-12,103-A), and S(+)- or dextro- oxaprotiline (dextroprotiline; CGP-12,104-A). Both enantiomers are active, with the levo- form acting merely as an antihistamine and the dextro- form having a more expansive pharmacology, but with both unexpectedly still retaining antidepressant effects.

Synonyms
  • Hydroxymaprotiline
Categories
UNII
3V3Z2HK4LS
CAS number
56433-44-4
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for the treatment of depression.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcarboseOxaprotiline may decrease the hypoglycemic activities of Acarbose.Approved, Investigational
AgmatineThe risk or severity of hypertension can be increased when Oxaprotiline is combined with Agmatine.Experimental, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Amikacin.Approved, Investigational, Vet Approved
BenzphetamineOxaprotiline may increase the vasopressor activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Oxaprotiline.Approved
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Botulinum Toxin Type B.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Oxaprotiline.Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Oxaprotiline.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Oxaprotiline.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Oxaprotiline.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxaprotiline.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Oxaprotiline.Approved, Investigational
ClindamycinThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Clindamycin.Approved, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Oxaprotiline.Approved, Illicit
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxaprotiline.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Cyclosporine.Approved, Investigational, Vet Approved
DapagliflozinOxaprotiline may decrease the hypoglycemic activities of Dapagliflozin.Approved
DesmopressinThe risk or severity of hyponatremia and water intoxication can be increased when Oxaprotiline is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Desvenlafaxine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxaprotiline.Approved
DexmethylphenidateThe serum concentration of Oxaprotiline can be increased when it is combined with Dexmethylphenidate.Approved, Investigational
DiethylpropionOxaprotiline may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Oxaprotiline.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxaprotiline.Approved, Investigational
DotarizineThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Dotarizine.Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxaprotiline.Approved, Vet Approved
EperisoneThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Eperisone.Approved, Investigational
EthanolOxaprotiline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Oxaprotiline.Approved
EtomidateThe risk or severity of hypertension can be increased when Oxaprotiline is combined with Etomidate.Approved
FentanylThe risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Oxaprotiline.Approved, Illicit, Investigational, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Oxaprotiline.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Fluoxetine.Approved, Vet Approved
FluspirileneThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Oxaprotiline.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Oxaprotiline.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Oxaprotiline.Approved, Investigational
GlimepirideOxaprotiline may decrease the hypoglycemic activities of Glimepiride.Approved
GlipizideOxaprotiline may decrease the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideOxaprotiline may decrease the hypoglycemic activities of Glyburide.Approved
GuanfacineThe risk or severity of hypertension can be increased when Oxaprotiline is combined with Guanfacine.Approved, Investigational
HydrocodoneOxaprotiline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxaprotiline.Approved
Insulin GlargineOxaprotiline may decrease the hypoglycemic activities of Insulin Glargine.Approved
Insulin HumanOxaprotiline may decrease the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproOxaprotiline may decrease the hypoglycemic activities of Insulin Lispro.Approved
IsocarboxazidThe therapeutic efficacy of Oxaprotiline can be increased when used in combination with Isocarboxazid.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Oxaprotiline.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Oxaprotiline.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Oxaprotiline.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Oxaprotiline.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Magnesium hydroxide.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Oxaprotiline can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Magnesium Trisilicate.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Oxaprotiline.Approved
MetforminOxaprotiline may decrease the hypoglycemic activities of Metformin.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Oxaprotiline.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Oxaprotiline.Approved, Investigational
NaphazolineOxaprotiline may increase the vasopressor activities of Naphazoline.Approved
NeomycinThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Neomycin.Approved, Vet Approved
NylidrinThe risk or severity of hypertension can be increased when Oxaprotiline is combined with Nylidrin.Approved
OndansetronThe risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Oxaprotiline.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxaprotiline.Approved, Illicit, Investigational
OxymetazolineOxaprotiline may increase the vasopressor activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Oxaprotiline.Approved, Investigational, Vet Approved
ParomomycinThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Oxaprotiline.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Oxaprotiline.Experimental
PhenobarbitalThe metabolism of Oxaprotiline can be increased when combined with Phenobarbital.Approved, Investigational
PhenylephrineOxaprotiline may increase the vasopressor activities of Phenylephrine.Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Polymyxin B Sulfate.Approved, Vet Approved
PramipexoleOxaprotiline may increase the sedative activities of Pramipexole.Approved, Investigational
PregabalinThe therapeutic efficacy of Oxaprotiline can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxaprotiline.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Oxaprotiline.Approved, Investigational
PseudoephedrineOxaprotiline may increase the vasopressor activities of Pseudoephedrine.Approved
PyrantelThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Pyrantel.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Oxaprotiline.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Oxaprotiline.Approved
RopiniroleOxaprotiline may increase the sedative activities of Ropinirole.Approved, Investigational
RosiglitazoneOxaprotiline may decrease the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SalbutamolThe risk or severity of hypertension can be increased when Oxaprotiline is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of hypertension can be increased when Oxaprotiline is combined with Salmeterol.Approved
SaxagliptinOxaprotiline may decrease the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxaprotiline.Approved, Investigational
SitagliptinOxaprotiline may decrease the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of seizure can be increased when Oxaprotiline is combined with Sodium phosphate, monobasic.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Oxaprotiline.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Oxaprotiline.Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Oxaprotiline.Approved
TramadolThe risk or severity of serotonin syndrome, sedation, and seizure can be increased when Oxaprotiline is combined with Tramadol.Approved, Investigational
TrimethadioneThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Trimethadione.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Oxaprotiline.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Oxaprotiline.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Venlafaxine.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Vinpocetine.Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Oxaprotiline.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Oxaprotiline.Approved, Investigational
ZolpidemOxaprotiline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Oxaprotiline.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910433
Wikipedia
Oxaprotiline

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on November 12, 2015 09:25 / Updated on August 02, 2018 06:17